Author of

• 20164

  +

  P1.15 - SCLC/Neuroendocrine Tumors (ID 701)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: SCLC/Neuroendocrine Tumors
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22786

    +

    P1.15-001 - Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer (ID 9379)

    09:30 - 09:30  |  Author(s): O. Arpí
    • Abstract
    • Slides

    Background:
    Cytokines are soluble proteins with a relevant role in immune response that can be modulated by immunotherapy. In this study we aimed to evaluate the serum concentrations of Th1/Th2 and inflammatory cytokines and their changes in SCLC patients treated with ipilimumab and chemotherapy compared to chemotherapy alone.
    
    Method:
    We evaluated 2 cohorts (C) of patients with SCLC: in C1, 47 patients were treated with standard platinum/etoposide (PE); in C2, 37 patients with ipilimumab, carboplatin and etoposide (ICE trial). We analyzed serum samples at baseline and subsequent time points with the Cytokine Human Magnetic 10-Plex (GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNF-α) plus MIP-1a. Serum samples from 30 healthy volunteers were used as controls. Statistical analysis was carried out with SPSS 22.0 (SPSS Inc.) and Prism 6.0 (GraphPad).
    
    Result:
    Patients with SCLC showed significantly lower levels of IL-1b, Mip-1a, IL-5 and IL-10 and higher TNF-a compared to healthy volunteers. Patients treated with chemotherapy alone (C1), showed a decrease of Th1 and inflammatory cytokine median concentrations at tumor response and an increase at progression, while no such pattern was observed in Th2 cytokines and TNF-a. In contrast, patients treated with ipilimumab in addition to chemotherapy (C2), showed a global increase on the level of all cytokines after treatment initiation (Figure 1).Figure 1
    
    
    
    Conclusion:
    In patients with SCLC, Th1 and inflammatory cytokines (except TNF-a) reflect tumor burden. Chemotherapy reduces these levels targeting cytokine secreting tumor cells. Th2 cytokines may be mainly secreted by immunological cells as they remain unaltered upon chemotherapy treatment. Interestingly, ipilimumab increases globally Th1, Th2 and inflammatory cytokine secretion counteracting the effect of chemotherapy. The correlation of these changes to outcome and toxicity warrants further investigation.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.